Genmab A/S (LON:0MGB)
London
· Delayed Price · Currency is GBP · Price in DKK | Market Cap | 9.34B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 869.80M |
| Shares Out | n/a |
| EPS (ttm) | 13.46 |
| PE Ratio | 10.73 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,753 |
| Average Volume | 67,193 |
| Open | 1,290.50 |
| Previous Close | 1,293.95 |
| Day's Range | 1,278.00 - 1,294.00 |
| 52-Week Range | 154.65 - 246.44 |
| Beta | 0.96 |
| RSI | 50.68 |
| Earnings Date | May 8, 2025 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.
Financial numbers in DKK Financial StatementsNews
Genmab's Outlook Beyond Darzalex's Patent Cliff
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha...
Genmab A/S Share Capital Reduction
Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 12, 2025, it was decided to reduce the Company's share capital with ...
Transactions In Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shar...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
Genmab drops as Bernstein cuts on Darzalex patent cliff
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or ...
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S' GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer c...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Genmab's Tivdak wins Japan's approval for ... Full story available on Benzinga.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Media Release COPENHAGEN, Denmark; March 27, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is bas...
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitments under the Restricted Stock Un...
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) Genmab categorically refutes allegations and will vigorously...
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory patient...
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational fola...
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
These large-cap stocks were the worst performers in the last week. Are they in your portfolio? Teradyne (NASDAQ: TER) shares dipped 20.08%. The company agreed to acquire Photonic IC Testing Company Q...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th...
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to consti...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management...
Genmab upgraded to Outperform at William Blair
Johnson and Johnson will not exercise worldwide license option for HexaBody-CD38, says Genmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,...